Portfolio of clients 2020 - present

Business development and interim-management becomes a long term commitment to develop a class III medical device for the next generation.  Fullfills operational director, R&D Director and Quality Director roles. Provides COO since 2024

Advisory and Operational Services 

Ongoing

Board and advisory services to the leadership team and investors.  Assisted in technical development and due diligence activities.

Advisory and Operational Services Concluded 2024

Business development and global market entry strategy later transitioning into operational role as Clinical Director. Ongoing growth and continued clinical excellence of the company following CE Mark

Advisory and Operational Services Concluded 2022

After a successful HUB program LLS took over the commercial directors position acting operationally to build the company securing Series A financing in July 2022. Developed commercial strategy, key accounts and partners. 

Series A July 2022 - Operational Services

Founding shareholder and CEO. Dr Wilson developed  the platform and took the product through clinical trials in competition with Googles' Verily Contact Lens.  Demonstrated the first clinical application of the sensor in human diabetic patients. Oversaw complete development in accordance with ISO 13485 including ASIC development , sensor validation, pre-clinical and clinical trials. 

EXITED 2020 to Private Equity

On behalf of the shareholders of the company advised the management on reshaping and refocusing the business strategy and relaunching in an ongoing change management process and advised on the exit to a strategic party in The Netherlands.

EXITED 2020 to Strategic Party

Co-developed and directed the HUB masterclass together with WhaleBay & Co. Sponsored by the Province of Zuid Holland and The City of Rotterdam. Supporting entrepreneurs in preparation for global market entry.  Worked with selected group of companies in a six month intensive program of coaching and mentoring culminating in bringing these companies to the USA. 

Partnership Zuid Holland and Gemeente Rotterdam

Listerdale LifeSciences BV provides expert subject matter advisory services in the life sciences and health industry on an ongoing basis to a number of investment and advisory companies.

Advisory Services 2020 - 2022

Listerdale LifeSciences BV provides expert subject matter advisory services in the life sciences and health industry on an ongoing basis to a number of investment and advisory companies.

Advisory Services 2020 - 2022

Supported the investors and management team in transitional activities and strategic planning. Facilitated contact with strategic parties and clinical and technical validation plan. 

Asset Divestment 2022

Founder of NovioTech incubator, working together with universities and first time entrepreneurs to develop cutting edge life science innovation.  

Divested 2020

Listerdale Life Sciences provided management board services representing the shareholders of NovioSpin BV. We engaged with the CEO in developing the business plan, R&D and product development plan along with long term strategy advice.

Project 2017

We represented the parent company providing expert guidance on regulatory and product development strategy along with drafting of the business plan and financial planning as well as working with first customers to determine product specifications

Spun out from parent company 2016

Listerdale Life Sciences assisted the CEO and COO of NovioCell in the development of its product portfolio in the ideation phase exploring potential application areas of its hydrogel technology

Consulted 2015 - 2016

Developed applications of a novel hydrogel material. Advising and providing expert subject matter assistance to Radboud University and University Medical Centre Nijmegen we identified and secured valuable IP rights in the application domains of cell growth and regenerative medicine

Established Spinout Companies 2015